Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Satellos Bioscience Inc T.MSCL

Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this... see more

TSX:MSCL - Post Discussion

Satellos Bioscience Inc > Severe covid-19 pill form medication
View:
Post by db2067 on Nov 25, 2021 9:12pm

Severe covid-19 pill form medication

I am not seeing any successful pill form medication for moderate to severe cases of Covid-19 - Merck / Pfizer are for early stage - they need to get people started with-in a few days. Skymount medical has talked about a formulation for patients with moderate to severe cases - this one may be oral amp b based. Moderate and severe testing:

RedHill BioPharma follows familiar biotech path after COVID-19 drug fails in severe patients https://www.fiercebiotech.com/biotech/redhill-biopharma-slides-as-covid-drug-flops-severe-disease

Laurent's COVID-19 pill fails phase 2, but data help narrow down patients who may benefit https://www.fiercebiotech.com/biotech/laurent-s-covid-19-pill-fails-phase-2-but-data-helps-narrow-down-patients-who-may-benefit

Mesoblast's Novartis-partnered COVID-19 cell therapy hits a wall as FDA requests new trial https://www.fiercebiotech.com/biotech/mesoblast-craters-again-as-fda-requests-another-trial-failed-covid-19-respiratory-treatment

CytoDyn digs deep for signs of efficacy in COVID-19 trial flop https://www.fiercebiotech.com/biotech/cytodyn-digs-deep-for-signs-efficacy-covid-19-trial-flop

Appili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial Evaluating Avigan®/Reeqonus™ https://ca.movies.yahoo.com/appili-therapeutics-provides-phase-3-121900866.html
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities